Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD40 activation: potential for specific immunotherapy in B-CLL.

M von Bergwelt-Baildon1, B Maecker, J Schultze

  • 1Department of Medical Oncology, Disease Center for Hematologic Neoplasia, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|May 21, 2004
PubMed
Summary

Chronic lymphocytic leukemia (CLL) needs new treatments as it is largely incurable. The CD40-CD40L interaction shows promise for improving immunotherapies against CLL by enhancing antigen presentation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trial.

ESMO open·2026
Same author

Correction: Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis.

Infection·2025
Same author

Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis.

Infection·2025
Same author

Diverse clinical manifestations of Parvovirus B19 infections during the 2024 outbreak in Germany.

Infection·2025
Same author

Early clinical trial unit tumor board: a real-world experience in a national cancer network.

Journal of cancer research and clinical oncology·2023
Same author

Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.

Journal of cancer research and clinical oncology·2023

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Chronic lymphocytic leukemia (CLL) remains largely incurable despite advances.
  • Current curative options like allogeneic transplantation carry high mortality risks.
  • There is a critical need for novel, less toxic therapeutic strategies for CLL.

Purpose of the Study:

  • To explore the potential of immunotherapeutic approaches for treating CLL.
  • To investigate the role of the CD40-CD40L interaction in enhancing anti-CLL immunity.
  • To discuss the biology and therapeutic applications of the CD40 system in CLL.

Main Methods:

  • Review of existing scientific literature on CLL, immunotherapy, and the CD40-CD40L pathway.
  • Analysis of the mechanisms by which CD40-CD40L interaction impacts antigen presentation in B-cells.

Related Experiment Videos

  • Discussion of potential therapeutic strategies leveraging the CD40 system for CLL treatment.

    • Main Results:

    • Immunotherapy demonstrates significant potential in treating CLL and other B-cell malignancies.
    • The CD40-CD40L interaction is crucial for increasing antigen presentation by both normal and malignant B-cells.
    • Targeting the CD40 system offers a promising avenue for developing effective CLL immunotherapies.

    Conclusions:

    • The CD40-CD40L pathway is a key target for enhancing immune responses against CLL.
    • Developing therapies that modulate CD40-CD40L interactions could lead to more effective and less toxic treatments for CLL.
    • Further research into the CD40 system holds significant promise for overcoming the incurability of CLL.